Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma. Read more about Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. Read more about Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology.
Awake glioma surgery: technical evolution and nuances. Read more about Awake glioma surgery: technical evolution and nuances.
Outcomes of sinonasal mucosal melanomas with endoscopic and open resection: a retrospective cohort study. Read more about Outcomes of sinonasal mucosal melanomas with endoscopic and open resection: a retrospective cohort study.
T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. Read more about T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
Advancing neuro-oncology of glial tumors from big data and multidisciplinary studies. Read more about Advancing neuro-oncology of glial tumors from big data and multidisciplinary studies.
Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. Read more about Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. Read more about A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma.
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Read more about Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Radiotherapy for recurrent intracranial epidermoid cysts without malignant transformation: a single-institution case series. Read more about Radiotherapy for recurrent intracranial epidermoid cysts without malignant transformation: a single-institution case series.
